⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29134071 | 0.73 | — | — | |
| SCHEMBL15994015 | 0.70 | — | — | |
| SCHEMBL7359252 | 0.69 | — | — | |
| SCHEMBL19892762 | 0.69 | ALDH1A1 (0.32) | — | |
| SCHEMBL9262915 | 0.67 | ALDH1A1 (0.31) | — | |
| Bicarbonate SCHEMBL23000816 | 0.65 | CYP1A2 (0.31) | — | |
| SCHEMBL10689998 | 0.65 | CES2 (0.38) | — | |
| SCHEMBL6036957 | 0.63 | — | — | |
| SCHEMBL22498238 | 0.62 | ALDH1A1 (0.36) | — | |
| SCHEMBL19970391 | 0.62 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536323-B2 | Modified nucleotides | PIERCE BIOTECHNOLOGY, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | PIERCE BIOTECHNOLOGY, INC. (US) | 2011-10-27 | — | — | US | claimed |
| WO-2023183345-A2 | METHOD OF SEQUENCING L-POLYNUCLEOTIDE | DXOME INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3795577-A1 | MODIFIED NUCLEOTIDES | Illumina Cambridge Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| US-20200399692-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| EP-3091026-B1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECH HOLDINGS CORP (KY) | 2019-02-20 | — | — | EP | disclosed |
| EP-3363809-A1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Illumina Cambridge Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160355541-A1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (KY) | 2016-12-08 | — | — | US | disclosed |
| EP-1530578-A2 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Solexa Limited (GB) | 2005-05-18 | — | — | EP | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| WO-2004018497-A2 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | SOLEXA LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| EP-1110088-A1 | ENERGY TRANSFER DYES | Amersham Pharmacia Biotech Inc (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000013026-A9 | ENERGY TRANSFER DYES | AMERSHAM PHARM BIOTECH INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000013026-A1 | ENERGY TRANSFER DYES | AMERSHAM PHARMACIA BIOTECH, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0709357-A1 | Method for the cross-coupling of aromatic halo compounds or perfluoroalkanesulphonates with terminal alkynes | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-01 | — | — | EP | disclosed |